Clinical Trials Logo

Clinical Trial Summary

A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients with chronic rhinosinusitis with or without nasal polyposis (NP).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03956862
Study type Interventional
Source Gossamer Bio Inc.
Contact
Status Completed
Phase Phase 2
Start date May 16, 2019
Completion date August 5, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06231004 - Correlation Between the Microbiome and Type 2 Inflammatory Diseases of CRSwNP
Recruiting NCT06338995 - A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) Phase 3